Evidence map›Paper›PMID 38804329›Full record

ArticleRevista espanola de salud publica2024

[What does Harm Reduction in Tobacco Use means to Public Health].

Javier Ayesta, Armando Peruga, Aarón Rebollar, Noa Rey, Andrés Zamorano, Susana Verdejo, Javier Panero, Julio César Doncel, Andrea Martín, Eva Mª Pérez-Sacristán

Abstract readEnglish Abstract
In one paragraph

Article in Revista espanola de salud publica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Javier AyestaProfesor de Farmacología. Universidad de Cantabria. Santander. España.
Armando PerugaEx Director de la Iniciativa Libre de Tabaco. Organización Mundial de la Salud (OMS). España.
Aarón RebollarUnidad de Prevención del Tabaquismo. Ministerio de Sanidad. Departamento de Salud, Salud Pública y Salud Alimentaria (TRAGSATEC). Madrid. España.
Noa ReySociedad Española de Especialistas en Tabaquismo. Madrid. España.
Andrés ZamoranoEx Presidente. Comité Nacional para la Prevención del Tabaquismo (CNPT). Madrid. España.
Susana VerdejoUnidad de Prevención del Tabaquismo. Ministerio de Sanidad. Madrid. España.
Javier PaneroUnidad de Prevención del Tabaquismo. Ministerio de Sanidad. Madrid. España.
Julio César DoncelUnidad de Prevención del Tabaquismo. Ministerio de Sanidad. Departamento de Salud, Salud Pública y Salud Alimentaria (TRAGSATEC). Madrid. España.
Andrea MartínUnidad de Prevención del Tabaquismo. Ministerio de Sanidad. Madrid. España.
Eva Mª Pérez-SacristánUnidad de Prevención del Tabaquismo. Ministerio de Sanidad. Departamento de Salud, Salud Pública y Salud Alimentaria (TRAGSATEC). Madrid. España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Harm reduction is a classic Public Health concept to refer to the reduction of the negative effect of drug use/abuse with a focus on justice and human rights, but the tobacco industry has been perverting this concept for years and using it as a tool for its own marketing. This publication details what real harm reduction action on tobacco use would be, when it should be implemented, and what pillars it should be based on. Different methods of reducing the harmful effects of tobacco and nicotine have been tried and tested over time, but the results have been poor; therefore, smoking cessation by the various officially recognised methods is recommended as a priority objective, using the tools that are truly supported by science. In contrast, it also explains the strategies developed by the industry to manipulate consumers and make them dependent on products that can eventually kill them: from the development of filtered cigarettes to light cigarettes, and from menthol to flavoured vapes. In all cases, they have falsely led people to believe that they were developing less toxic products when they were not. Nowadays, both light and menthol cigarettes are banned in Spain, filters have not reduced risk but increased the use, and vapes try to replace cigarettes with their attractive flavours and their false legend of healthier products when what they are really doing is maintaining the same addiction by changing the object, encouraging dual use, and attracting younger and younger non-smokers. At the same time, a strategy of dividing the opinion of health professionals has been developed, using medical doctors and researchers with recognised conflicts of interest but who manage to confuse consumers. In conclusion, we consider that, although nicotine releasing devices may be useful elements in some particular cases, they are not recommended at the population level as they can promote onset, prevent cessation, as well as maintaining the addictive capacity. The only nicotine products that are recommended are those of pharmacological use approved for the case and provided they are used as a transitional tool to complete cessation.

Indexed as

Harm ReductionPublic HealthHumansSmoking CessationSpainTobacco IndustryTobacco UseCessationCigarettesConflict of interestHarm reductionNicotine releasing devices.Public HealthSpainStrategiesTobacco industryVapes

Identifiers

PMID38804329
PMCPMC11575274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.